30 April 2020

FoRx Therapeutics AG, a Basel-based biotechnology company developing a new generation of cancer drugs focusing on novel DNA Replication Stress (DRS) pathways activated in cancer, completes a EUR 10M seed-financing round led by M Ventures (venture capital arm of Merck), Novartis Venture Fund and Omega Funds. Pfizer Ventures, the venture capital arm of Pfizer Inc. (NYSE: PFE) and LSP (Life Sciences Partners) also joined the seed-financing.

VISCHER advises FoRx Therapeutics AG on all Swiss legal issues related to the transaction. The VISCHER team includes Christian Wyss (Partner, Life Sciences), Dania Salvisberg-Schneider (Associate, Corporate / M&A), Luzius Zumstein (Associate, Corporate / M&A), Fiona Gao (Associate, Life Sciences), Beatrice Leistner (Associate, Tax), and Gian Geel (Associate, Employment).

Press release FoRx Therapeutics AG

Categories: Employment Law, Corporate and Commercial, Life Sciences, Pharma, Biotech, Mergers & Acquisitions, Tax

You are currently offline. Some pages or content may fail to load.